T-cell lymphoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 17 Jun 2026 04:02:09 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png T-cell lymphoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of dapagliflozin to prevent heart complications during lymphoma treatment in patients receiving first-line therapy https://clinicaltrials.eu/trial/study-of-dapagliflozin-to-prevent-heart-complications-during-lymphoma-treatment-in-patients-receiving-first-line-therapy/ Wed, 29 Apr 2026 15:06:52 +0000 https://clinicaltrials.eu/trial/study-of-dapagliflozin-to-prevent-heart-complications-during-lymphoma-treatment-in-patients-receiving-first-line-therapy/ This study focuses on patients with different types of lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, and T-cell lymphomas. The research examines whether a medication called dapagliflozin can protect the heart from potential damage during standard cancer treatment. Dapagliflozin belongs to a group of medications known as SGLT2 inhibitors, which are typically used to treat diabetes.

The study will test if taking dapagliflozin while receiving standard lymphoma treatment can help prevent heart-related side effects. Participants will receive either dapagliflozin or placebo tablets for 6 months while undergoing their regular cancer treatment. The medication or placebo will be taken by mouth once daily.

During the study, doctors will monitor heart function using various tests to measure how well the heart is working. These tests include examining heart muscle movement, blood flow patterns, and checking certain substances in the blood that can indicate heart health. The study will also track any heart-related symptoms that participants may experience during their treatment.

]]> Study of Fadraciclib in Adults with Advanced Solid Tumors (Including Breast, Colorectal, Endometrial, Ovarian, Biliary Tract, and Liver Cancer) and Lymphoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-fadraciclib-for-patients-with-advanced-solid-tumors-and-lymphoma/ Wed, 29 Apr 2026 15:00:59 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-fadraciclib-for-patients-with-advanced-solid-tumors-and-lymphoma/ This clinical trial studies the effects of fadraciclib (also known as CYC065) in people with various types of advanced cancers. The study focuses on several types of solid tumors and lymphoma, including endometrial cancer, ovarian cancer, biliary tract cancer, hepatocellular carcinoma, B-cell lymphoma, T-cell lymphoma, metastatic colorectal cancer, and different types of breast cancer.

The medication being tested, fadraciclib, is taken by mouth in tablet form. It belongs to a group of drugs called CDK2/9 inhibitors, which work by blocking certain proteins that help cancer cells grow. The study aims to find the best dose of the medication and determine how well it works in treating these different types of cancer.

During the study, participants take the medication either once or twice daily in 28-day cycles. The treatment continues as long as it is helping and the side effects are manageable. Throughout the study, doctors monitor the participants’ health and how their cancer responds to the treatment. This includes regular check-ups and various medical tests to ensure safety and track the effectiveness of the medication.

]]> Study of CD7-CART01, Cyclophosphamide, and Fludarabine Phosphate for Children and Young Adults with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma https://clinicaltrials.eu/trial/study-of-cd7-cart01-cyclophosphamide-and-fludarabine-phosphate-for-children-and-young-adults-with-relapsed-or-refractory-t-cell-acute-lymphoblastic-leukemia-lymphoma/ Wed, 29 Apr 2026 14:30:05 +0000 https://clinicaltrials.eu/trial/study-of-cd7-cart01-cyclophosphamide-and-fludarabine-phosphate-for-children-and-young-adults-with-relapsed-or-refractory-t-cell-acute-lymphoblastic-leukemia-lymphoma/ This clinical trial is focused on studying a type of blood cancer called relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/Lymphoma, which affects children and young adults. The study is testing a new treatment called CD7-CART01, which involves using specially modified cells to target and fight the cancer. This treatment is being compared to standard treatments, which include medications like Cyclophosphamide and Fludarabine Phosphate. These medications are given as injections or infusions, which means they are delivered directly into the bloodstream.

The purpose of the study is to find out if the new treatment is safe and to determine the best dose to use. The study is divided into two phases. In the first phase, the focus is on ensuring the safety of the treatment and finding the right dose. In the second phase, the study will look at how well the treatment works at the dose found in the first phase. Participants will receive the treatment and be monitored closely by healthcare professionals to see how their bodies respond.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the effects of the treatment. The study aims to provide valuable information that could lead to better treatment options for those affected by this type of cancer. The study is expected to continue until 2028, with recruitment starting in 2024.

]]> Study on the Safety and Effectiveness of LIS1 for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-lis1-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma-ptcl/ Wed, 29 Apr 2026 14:29:50 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-lis1-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma-ptcl/ This clinical trial is focused on studying a type of cancer called Peripheral T-cell Lymphoma (PTCL), which is a rare and aggressive form of non-Hodgkin lymphoma affecting the T-cells, a type of white blood cell. The study is testing a new treatment called LIS1, which is a glyco-humanized polyclonal antibody. This means it is a specially designed protein that targets and binds to specific cells in the body, in this case, the tumoral T-cells involved in PTCL. The treatment is administered as a concentrate for solution for infusion, meaning it is given directly into the bloodstream through an intravenous infusion.

The purpose of the study is to evaluate the safety and effectiveness of LIS1 in patients whose PTCL has returned or has not responded to previous treatments. The study is divided into two parts. In the first part, the focus is on determining the safest dose of LIS1 by gradually increasing the dose given to participants. This helps identify the maximum dose that can be tolerated without causing severe side effects. In the second part, the study will assess how well LIS1 works in treating PTCL by observing its effects on the cancer.

Participants in the study will receive LIS1 and will be monitored closely for any side effects and changes in their condition. The study aims to find out if LIS1 can effectively reduce the size of the tumors or slow down the progression of the disease. This research is important for developing new treatment options for patients with relapsed or refractory Peripheral T-cell Lymphoma.

]]> Study of Tolinapant with Decitabine and Cedazuridine for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma https://clinicaltrials.eu/trial/study-of-tolinapant-with-decitabine-and-cedazuridine-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma/ Wed, 29 Apr 2026 14:25:04 +0000 https://clinicaltrials.eu/trial/study-of-tolinapant-with-decitabine-and-cedazuridine-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma/ This clinical trial is focused on studying a type of cancer called Peripheral T-cell Lymphoma (PTCL), which is a cancer of the immune system’s T-cells. The study is specifically for patients whose cancer has returned or has not responded to previous treatments, known as relapsed/refractory Peripheral T-cell Lymphoma (R/R PTCL). The trial will test the safety and effectiveness of a new treatment combination. This includes a medication called Tolinapant, which is taken as a capsule, and a combination of two substances, Decitabine and Cedazuridine, which are taken as a tablet.

The purpose of the study is to find out how safe these treatments are and how well they work in treating R/R PTCL. The study will be conducted in two phases. In the first phase, researchers will determine the safest dose of Tolinapant when used with Decitabine/Cedazuridine. In the second phase, they will evaluate how effective the treatment is in reducing the cancer. Participants will receive either the combination of Tolinapant with Decitabine/Cedazuridine or Decitabine/Cedazuridine alone. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects.

Throughout the study, participants will take the medications orally, meaning by mouth. The study will monitor the participants’ health and any side effects they may experience. The trial aims to provide valuable information on whether this combination of treatments can help manage R/R PTCL more effectively. The study is expected to continue until 2026, with the goal of improving treatment options for patients with this challenging form of cancer.

]]>